GLP Watchdog

Best TB-500 Providers in 2026 — Ranked & Reviewed

What TB-500 is sold as is a fragment, or an equivalent, of thymosin beta-4, a protein the body already uses in cell migration, wound healing and tissue repair. Recovery is the usual context, and BPC-157 is usually mentioned in the same breath. Most of the online market treats it as an unregulated “research chemical” — no prescriber anywhere in the transaction, no clinical oversight either — and no compounding pharmacy may lawfully sell it either. The current status is below.

New to TB-500? Read our full TB-500 guide — evidence, dosing, safety and side effects.

Some of the links on this page earn us money. If you sign up with a provider after following one, that provider may pay GLP Watchdog a commission. Learn more

By Ruth Calder · Enforcement Editor
Editorially reviewed (not clinically reviewed). Not medical advice · How we verify contentLast reviewed

Why nothing is ranked here yet

On July 23, 2026 the Pharmacy Compounding Advisory Committee (PCAC) at the FDA voted to recommend that TB-500 be added to Section 503A's Bulk Drug Substances List. Real progress, and still only a recommendation: formal action by the FDA and HHS has to follow before any compounding pharmacy may lawfully sell TB-500 again. We audited the catalog and could confirm no provider selling it in full compliance, so we rank none until that position changes.

Listing a provider that cannot legally sell this yet would be worse than listing nobody, so nothing is shown. The FDA’s decision is being tracked, and a compliant provider will be ranked here the moment one exists.

How we rank, and what counts as “legit”

Scoring for every provider on this page runs against our published six-factor rubric[1]: value, effectiveness, user experience, trust & safety, accessibility and support.

Each of Wegovy, Zepbound, Ozempic and Mounjaro holds its own separate FDA approval under its own NDA number[4][5]. Published Phase 3 efficacy for semaglutide at 2.4 mg (~14.9% mean weight loss across 68 weeks) comes from STEP 1[6]; those for tirzepatide (~20.9% at the 15 mg dose over 72 weeks) come from SURMOUNT-1[7]. In 2025 the SURMOUNT-5 head-to-head set the two against each other[8].

How much of an anti-obesity medication is covered varies widely between state Medicaid programs and between commercial plans[9][10]. Under IRS Publication 502, compounded GLP-1s and brand-name ones alike are generally FSA/HSA eligible where a prescription exists[11].

Price and states served both move. Read them off the seller's own site before you enroll.How our reviews work →

Frequently Asked Questions

Six weighted dimensions produce the score. Value (25%) and Effectiveness (25%) carry the most, then User Experience (15%) and Trust & Safety (15%), then Accessibility (10%) and Support (10%). Behind them sits our research into pricing data, clinical evidence, user reviews and publicly available information. Those weights then combine into one overall score out of 10.
The six-dimension methodology computes each score on its own, and no commercial relationship ever moves a provider's underlying number. Every provider's full score sits on its card for you to check. Some providers do hold affiliate agreements with us, which means a commission reaches us if you click through and buy. On the lists carrying the highest commercial intent — the weight-loss injection and shot lists, the semaglutide and tirzepatide lists, the compounded and cheapest molecule lists, and the fitness-app list — affiliate partners take the top positions. Every other list runs in score order, or in price order on the cheapest lists. That placement is disclosed here, on our methodology page, and on our affiliate-disclosure page.
Sources & methodology — as of September 2026
  1. 1.GLP Watchdog — GLP-1 Pricing Index 2026 (our independent dataset)— GLP Watchdog.
  2. 2.FDA — Compounding and the 503A Pharmacy Framework— U.S. Food & Drug Administration.
  3. 3.FDA — Drug Shortages Database (current shortage listings)— U.S. Food & Drug Administration.
  4. 4.FDA — Wegovy (semaglutide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  5. 5.FDA — Zepbound (tirzepatide) Approval History via Drugs@FDA— U.S. Food & Drug Administration.
  6. 6.STEP 1 Trial — Once-Weekly Semaglutide in Adults with Overweight or Obesity (Wilding JPH et al.)— New England Journal of Medicine.PMID: 33567185.
  7. 7.SURMOUNT-1 Trial — Tirzepatide Once Weekly for the Treatment of Obesity (Jastreboff AM et al.)— New England Journal of Medicine.PMID: 35658024.
  8. 8.SURMOUNT-5 Trial — Tirzepatide vs. Semaglutide Head-to-Head in Obesity (Garvey WT et al.)— New England Journal of Medicine.PMID: 40334173.
  9. 9.KFF — Medicaid coverage research (anti-obesity & GLP-1 drug policy)— Kaiser Family Foundation.
  10. 10.CMS — Medicaid prescription drug coverage policy (state-by-state)— Centers for Medicare & Medicaid Services.
  11. 11.IRS Publication 502 — Medical and Dental Expenses (HSA/FSA eligibility)— Internal Revenue Service.

Related Rankings